Profile data is unavailable for this security.
About the company
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.
- Revenue in INR (TTM)27.12bn
- Net income in INR32.40m
- Incorporated2007
- Employees1.13k
- LocationDishman Carbogen Amcis LtdDishman Corporate HouseIscon-Bopal Road, AmbliAHMEDABAD 380058IndiaIND
- Phone+91 2 717420100
- Fax+91 7 926420198
- Websitehttps://www.carbogen-amcis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gujarat Themis Biosyn Ltd | 1.51bn | 487.73m | 26.42bn | 160.00 | 82.99 | 16.29 | 48.78 | 17.52 | 4.47 | 4.47 | 13.83 | 22.79 | 0.5773 | 13.98 | 5.18 | -- | 18.67 | 30.70 | 20.08 | 34.37 | 61.20 | 68.03 | 32.34 | 35.51 | 2.28 | 174.42 | 0.1093 | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
Panacea Biotec Ltd | 5.59bn | -83.70m | 26.80bn | 1.15k | -- | 3.21 | 102.72 | 4.79 | -1.39 | -1.39 | 91.13 | 136.29 | 0.4419 | 1.02 | 8.60 | -- | -0.6892 | 13.08 | -0.9363 | 19.61 | 64.31 | 50.69 | -1.56 | 30.99 | 0.9034 | -15.65 | 0.026 | -- | -0.014 | 0.5464 | -613.56 | -- | 48.74 | -- |
IOL Chemicals and Pharmaceuticals Ltd | 20.79bn | 1.01bn | 27.14bn | 2.78k | 26.85 | 1.61 | 15.68 | 1.31 | 3.44 | 3.44 | 70.85 | 57.50 | 0.8988 | 3.54 | 4.22 | -- | 4.37 | 10.26 | 5.85 | 13.42 | 33.06 | 32.77 | 4.86 | 9.33 | 1.30 | 8.83 | 0.0649 | -- | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | -- |
Solara Active Pharma Sciences Ltd | 12.84bn | 5.40m | 30.76bn | 2.16k | -- | 3.04 | 30.82 | 2.40 | -0.1753 | -0.1753 | 375.11 | 227.72 | 0.5603 | 1.85 | 3.80 | -- | 0.0236 | -3.27 | 0.0452 | -5.35 | 51.21 | 41.54 | 0.0421 | -6.17 | 0.4352 | 0.9322 | 0.4205 | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
Indoco Remedies Ltd | 16.65bn | -737.30m | 31.24bn | 5.93k | -- | 3.06 | 86.99 | 1.88 | -8.45 | -8.45 | 168.75 | 110.79 | 0.7279 | 1.29 | 4.39 | -- | -3.41 | 4.84 | -4.94 | 6.87 | 70.08 | 66.53 | -4.68 | 5.16 | 0.7203 | -0.22 | 0.4938 | 15.44 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
Morepen Laboratories Ltd | 18.12bn | 1.18bn | 34.65bn | 1.62k | 28.74 | 3.00 | 23.57 | 1.91 | 2.20 | 2.20 | 33.38 | 21.10 | 1.18 | 4.23 | 5.56 | -- | 7.69 | 8.14 | 11.04 | 12.81 | 36.01 | 33.88 | 6.51 | 5.91 | 1.72 | 17.39 | 0.0813 | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
Zota Health Care Ltd | 2.93bn | -563.98m | 36.41bn | 445.00 | -- | 15.48 | -- | 12.43 | -20.74 | -20.74 | 107.84 | 78.12 | 0.8779 | 1.72 | 8.65 | -- | -17.00 | -7.79 | -23.17 | -10.57 | 53.13 | 42.76 | -19.37 | -8.01 | 0.78 | -4.54 | 0.3806 | -- | 62.32 | 25.23 | -293.08 | -- | 49.40 | 0.00 |
Gufic BioSciences Ltd | 8.20bn | 696.49m | 38.65bn | 1.45k | 55.46 | 6.43 | 42.61 | 4.71 | 6.95 | 6.95 | 81.80 | 59.94 | 0.7249 | 1.80 | 2.54 | -- | 6.16 | 10.27 | 9.27 | 16.11 | 54.29 | 47.54 | 8.50 | 10.48 | 1.05 | 4.92 | 0.3587 | -- | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
Dishman Carbogen Amcis Ltd | 27.12bn | 32.40m | 41.38bn | 1.13k | 1,256.67 | 0.7095 | 13.93 | 1.53 | 0.21 | 0.21 | 173.66 | 371.95 | 0.277 | 0.5627 | 4.82 | -- | 0.0331 | -0.7247 | 0.0429 | -0.9005 | 81.50 | 75.60 | 0.1195 | -2.77 | 0.6755 | 1.12 | 0.2906 | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
RPG Life Sciences Ltd | 6.53bn | 1.83bn | 42.15bn | 1.33k | 23.01 | 7.95 | 20.60 | 6.45 | 110.79 | 110.79 | 395.10 | 320.77 | 1.12 | 2.21 | 9.62 | 4,909,317.00 | 31.30 | 21.05 | 39.84 | 27.78 | 67.25 | 63.28 | 28.04 | 16.68 | 3.11 | 222.94 | 0.00 | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
Hikal Ltd | 18.60bn | 908.00m | 43.41bn | 2.06k | 33.09 | 3.44 | 19.28 | 2.33 | 10.64 | 10.64 | 169.08 | 102.38 | 0.7415 | 2.62 | 3.47 | -- | 3.62 | 4.78 | 5.23 | 7.00 | 54.98 | 48.41 | 4.88 | 5.71 | 0.8371 | 2.58 | 0.3773 | 17.14 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
Unichem Laboratories Ltd | 20.29bn | 1.51bn | 44.42bn | 3.33k | 29.59 | 1.81 | 16.60 | 2.19 | 21.32 | 21.32 | 287.32 | 348.07 | 0.5929 | 0.9107 | 2.85 | 6,098,177.00 | 4.40 | -0.5598 | 5.89 | -0.6977 | 61.01 | 55.09 | 7.42 | -1.18 | 1.04 | 7.28 | 0.158 | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
Aarti Drugs Ltd | 23.87bn | 1.68bn | 47.26bn | 1.06k | 28.16 | 3.45 | 21.11 | 1.98 | 18.39 | 18.39 | 260.98 | 149.99 | 0.9535 | 3.22 | 3.28 | -- | 6.71 | 9.09 | 9.96 | 14.39 | 35.40 | 24.67 | 7.04 | 8.08 | 1.03 | 6.45 | 0.31 | -- | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | -- |
SeQuent Scientific Ltd | 15.51bn | 218.80m | 47.35bn | 1.20k | 222.89 | 6.73 | 47.97 | 3.05 | 0.85 | 0.85 | 59.96 | 28.15 | 0.9874 | 2.22 | 4.44 | -- | 2.05 | 0.4014 | 3.42 | 0.6553 | 47.67 | 42.75 | 2.08 | 0.42 | 0.9655 | 1.60 | 0.3845 | -- | 13.26 | 5.64 | 161.00 | -20.73 | -0.8147 | -- |
Sun Pharma Advanced Research Co Ltd | 717.70m | -3.43bn | 52.38bn | 409.00 | -- | -- | -- | 72.99 | -10.56 | -10.56 | 2.21 | -6.69 | 0.1688 | -- | 2.96 | -- | -80.54 | -60.53 | -324.23 | -129.98 | 67.79 | 78.69 | -477.23 | -168.34 | -- | -37.12 | 5.17 | -- | -5.00 | -1.35 | 11.55 | -- | -28.16 | -- |
Innova Captab Ltd | 12.44bn | 1.28bn | 53.07bn | 1.95k | 41.40 | 5.53 | 34.68 | 4.27 | 22.40 | 22.40 | 217.24 | 167.66 | 0.8573 | 4.63 | 4.01 | 6,377,826.00 | 8.84 | 10.02 | 11.24 | 15.00 | 34.54 | 27.20 | 10.31 | 8.72 | 1.38 | 67.10 | 0.2606 | -- | 15.02 | 27.21 | 35.95 | 35.69 | 109.94 | -- |
Holder | Shares | % Held |
---|---|---|
HBM Partners AG (Investment Management)as of 31 Dec 2024 | 5.56m | 3.55% |
Dimensional Fund Advisors LPas of 04 Jul 2025 | 1.49m | 0.95% |
HSBC Asset Management (India) Pvt Ltd.as of 30 Jun 2025 | 1.48m | 0.94% |
SSgA Funds Management, Inc.as of 02 Jul 2025 | 249.95k | 0.16% |
Motilal Oswal Asset Management Co. Ltd.as of 30 Jun 2025 | 207.02k | 0.13% |
American Century Investment Management, Inc.as of 02 Jul 2025 | 167.46k | 0.11% |
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 2025 | 115.38k | 0.07% |
Dimensional Fund Advisors Ltd.as of 04 Jul 2025 | 78.73k | 0.05% |
DFA Australia Ltd.as of 31 May 2025 | 13.43k | 0.01% |
Bandhan AMC Ltd.as of 31 May 2025 | 1.05k | 0.00% |